|
|
Home > Healthcare > Pharmaceutical > Drug Discovery
Immune/Inflammatory Disease: Early-Stage R&D Technologies and Dealmaking
|
| Published Date:
May 2009
Published By:
Decision Resources
Page Count:
24
Order Code:
R55-645
|
|
|
|
Introduction
Today’s leading autoimmune/inflammatory disease drugs are blockbusters, but what are the remaining unmet needs and next opportunities? Dealmaking patterns indicate that Big Pharma continues to look to small technology companies to tap opportunities to treat underserved diseases and offer improved administration options. While the value of the novel agents in development remains unproved, earlystage platforms and pipelines house the next innovations in these disease states.
Get the Answers You Need to Shape Your Strategy
- Although efficacious, current therapies for inflammatory and autoimmune diseases do not successfully
treat all patients. What novel mechanisms of action are in development? What technologies offer treatment potential?
- Much of the innovation in drug discovery and design occurs in small companies. What companies are developing novel approaches to treat inflammatory diseases? What collaborations have they forged with Big Pharma?
- Although the inflammatory cascade is central to most of the autoimmune diseases, the specific etiology
of many diseases remains unknown. What are companies doing to further the understanding of these diseases?
Scope
- Current market: 2008 sales, market-leading products, leading companies.
- Novel targets for drug development: MAP kinases, Janus kinases, toll-like receptors,novel interleukins, NF-ęB, PDE4.
- Novel technologies for drug development: RNA therapeutics, stem-cell therapy.
- Development and dealmaking data: 8 tables that identify developmental compounds and industry and academic alliances.
- Company profiles: Archemix, Array BioPharma, Cellzome, Dynavax, Regulus Therapeutics.
|
Similar Products
Antidiabetics in Australia Market Forecast
Published Oct 2009 by Datamonitor
Plunkett's Health Care Technologies Overview 2010 (Summary)
Published Oct 2009 by Plunkett Research, Ltd.
Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market
Published Oct 2009 by Datamonitor
Commercial Insight: Parkinson's Disease - Japan and Europe to drive total market growth
Published Oct 2009 by Datamonitor
Commercial Insight: Antidepressants - Novel mechanism offers hope in depressed market
Published Oct 2009 by Datamonitor
Parkinson's Disease Market Forecast
Published Oct 2009 by Datamonitor
Orphan Drug Strategies
Published Oct 2009 by Datamonitor
Pipeline Insight: HIV - The Age of Convenience
Published Oct 2009 by Datamonitor
The World Market for Addiction Disorders, 2009 - 2016
Published Oct 2009 by Spectra Intelligence
|
|
|
|
0 items
